Pfizer, BioNTech give details about mRNA COVID-19 vaccine deal
Biopharmaceutical New Technologies (BioNTech) and Pfizer have released additional details regarding their collaboration to advance the mRNA COVID-19 vaccine candidate BNT162. Pfizer will pay up to $748 million to BioNTech.
MilliporeSigma awarded U.S. patent for new CRISPR technology
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second CRISPR patent granted to the company in the U.S. and its 23rd CRISPR-related patent worldwide.
Boehringer Ingelheim expands COVID-19 collaborations
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic collaboration partners for therapy development.
Avectas nets patent for cell engineering technology
Avectas has received a patent for its Solupore cell engineering technology.
Arrakis Therapeutics partners with Roche
Biopharmaceutical firm Arrakis Therapeutics has inked a license agreement with Roche to collaborate on research of Roche's RNA-targeted small-molecule drugs.
AI engine analyzes over 50,000 novel coronavirus papers
Clinical artificial intelligence (AI) software developer Mendel said it has developed an AI-based search engine that can analyze more than 50,000 novel coronavirus research papers and answer COVID-19-related questions.
AACC reschedules meeting with safety in mind
After deciding to postpone its annual scientific meeting due to COVID-19, The American Association for Clinical Chemistry (AACC) has rescheduled the meeting and clinical lab expo for December 13-17 in Chicago
Gladstone Institutes launches COVID-19 fund
Gladstone Institutes is seeking donations to mobilize resources and start research projects to help fight the COVID-19 pandemic.
Applied DNA, Takis expand COVID-19 vaccine development
Applied DNA and Takis Biotech have added a fifth candidate to their COVID-19 vaccine development program, increasing the chances of a successor emerging.
Modalis gains foundational CRISPR IP access
Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.